EA201790520A1 - Способы лечения аутоиммунного заболевания с применением доменного антитела, специфического к cd40l - Google Patents
Способы лечения аутоиммунного заболевания с применением доменного антитела, специфического к cd40lInfo
- Publication number
- EA201790520A1 EA201790520A1 EA201790520A EA201790520A EA201790520A1 EA 201790520 A1 EA201790520 A1 EA 201790520A1 EA 201790520 A EA201790520 A EA 201790520A EA 201790520 A EA201790520 A EA 201790520A EA 201790520 A1 EA201790520 A1 EA 201790520A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antibodies
- graphoteras
- methods
- cd40l
- autoimmune disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
В настоящем изобретении предусматриваются способы лечения аутоиммунного заболевания, например, такого как первичная иммунная тромбоцитопения (ITP), отторжение трансплантата цельного органа, заболевание, связанное с трансплантацией, обыкновенная пузырчатка, системная склеродермия и тяжёлая псевдопаралитическая миастения, с использованием полипептидов антител, которые специфически связывают человеческий CD40L. Полипептиды антитела не активируют тромбоциты. Эти способы могут охватывать по меньшей мере один цикл введения, включающий одну дозу полипептида антитела. Дозу можно вводить внутривенно в количестве от примерно 75 до примерно 1500 мг. Этот способ нормализует количество тромбоцитов у больного человека.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462048459P | 2014-09-10 | 2014-09-10 | |
PCT/US2015/049338 WO2016040571A1 (en) | 2014-09-10 | 2015-09-10 | Methods of treating autoimmune disease using a domain antibody directed against cd40l |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201790520A1 true EA201790520A1 (ru) | 2017-07-31 |
Family
ID=54207743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201790520A EA201790520A1 (ru) | 2014-09-10 | 2015-09-10 | Способы лечения аутоиммунного заболевания с применением доменного антитела, специфического к cd40l |
Country Status (13)
Country | Link |
---|---|
US (3) | US20170306034A1 (ru) |
EP (1) | EP3191522A1 (ru) |
JP (1) | JP2017528466A (ru) |
KR (1) | KR20170052627A (ru) |
CN (1) | CN106687133A (ru) |
AU (1) | AU2015315063A1 (ru) |
BR (1) | BR112017004590A2 (ru) |
CA (1) | CA2960819A1 (ru) |
EA (1) | EA201790520A1 (ru) |
IL (1) | IL251025A0 (ru) |
MX (1) | MX2017002841A (ru) |
SG (1) | SG11201701769TA (ru) |
WO (1) | WO2016040571A1 (ru) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4265267A3 (en) | 2010-10-19 | 2024-01-17 | Op-T LLC | Peptides for modulating t-cell activity and uses thereof |
EA201790520A1 (ru) | 2014-09-10 | 2017-07-31 | Бристол-Маерс Сквибб Компани | Способы лечения аутоиммунного заболевания с применением доменного антитела, специфического к cd40l |
US11793854B2 (en) * | 2019-03-21 | 2023-10-24 | Op-T Llc | Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000072882A1 (fr) * | 1999-06-01 | 2000-12-07 | Eisai Co., Ltd. | Agents prophylactiques du purpura thrombocytopenique idiopathique |
PL2125894T3 (pl) * | 2007-03-22 | 2019-08-30 | Biogen Ma Inc. | Białka wiążące, w tym przeciwciała, pochodne przeciwciał i fragmenty przeciwciał, które swoiście wiążą się z CD154 i ich zastosowania |
TWI585102B (zh) * | 2011-10-13 | 2017-06-01 | 必治妥美雅史谷比公司 | 拮抗cd40l之抗體多肽 |
EA201790520A1 (ru) | 2014-09-10 | 2017-07-31 | Бристол-Маерс Сквибб Компани | Способы лечения аутоиммунного заболевания с применением доменного антитела, специфического к cd40l |
-
2015
- 2015-09-10 EA EA201790520A patent/EA201790520A1/ru unknown
- 2015-09-10 KR KR1020177009210A patent/KR20170052627A/ko unknown
- 2015-09-10 EP EP15771821.4A patent/EP3191522A1/en not_active Withdrawn
- 2015-09-10 US US15/510,507 patent/US20170306034A1/en not_active Abandoned
- 2015-09-10 SG SG11201701769TA patent/SG11201701769TA/en unknown
- 2015-09-10 JP JP2017513430A patent/JP2017528466A/ja active Pending
- 2015-09-10 MX MX2017002841A patent/MX2017002841A/es unknown
- 2015-09-10 WO PCT/US2015/049338 patent/WO2016040571A1/en active Application Filing
- 2015-09-10 BR BR112017004590A patent/BR112017004590A2/pt not_active Application Discontinuation
- 2015-09-10 AU AU2015315063A patent/AU2015315063A1/en not_active Abandoned
- 2015-09-10 CA CA2960819A patent/CA2960819A1/en not_active Abandoned
- 2015-09-10 CN CN201580048172.9A patent/CN106687133A/zh active Pending
-
2017
- 2017-03-08 IL IL251025A patent/IL251025A0/en unknown
-
2020
- 2020-02-20 US US16/795,823 patent/US11466091B2/en active Active
-
2022
- 2022-09-21 US US17/934,012 patent/US20230295321A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2017528466A (ja) | 2017-09-28 |
US20230295321A1 (en) | 2023-09-21 |
WO2016040571A1 (en) | 2016-03-17 |
EP3191522A1 (en) | 2017-07-19 |
IL251025A0 (en) | 2017-04-30 |
SG11201701769TA (en) | 2017-04-27 |
MX2017002841A (es) | 2017-05-30 |
CN106687133A (zh) | 2017-05-17 |
AU2015315063A1 (en) | 2017-04-27 |
BR112017004590A2 (pt) | 2017-12-05 |
US20170306034A1 (en) | 2017-10-26 |
CA2960819A1 (en) | 2016-03-17 |
US11466091B2 (en) | 2022-10-11 |
KR20170052627A (ko) | 2017-05-12 |
US20200216552A1 (en) | 2020-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022002018A (es) | Anticuerpos de union a cd3. | |
CO2019007844A2 (es) | Anticuerpo anti-receptor de transferrina humana novedoso capaz de penetrar la barrera hematoencefálica | |
MX2018016404A (es) | Anticuerpos de union a cd3. | |
MX2020006715A (es) | Anticuerpos especificos del heterodimero de cd3-delta/epsilon. | |
PH12018501882A1 (en) | Binding proteins and methods of use thereof | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
EA201890285A1 (ru) | Антитела против pd-1, активируемые антитела против pd-1 и способы их применения | |
EA201790961A1 (ru) | Перенацеливающие cd3/cd38 t-клетки гетеродимерные иммуноглобулины и способы их получения | |
EA201892294A1 (ru) | Антитела и композиции против tim-3 | |
GEP20207166B (en) | Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use | |
EA202191380A1 (ru) | Антитела к альфа-синуклеину и их применение | |
MX2015016111A (es) | Anticuerpos anti-b7-h5 y sus usos. | |
JOP20170004B1 (ar) | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته | |
EA201991005A1 (ru) | Антитела и полипептиды, направленные против cd127 | |
MX2018003411A (es) | Terapia glucodirigida. | |
PE20211293A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
EA201691634A1 (ru) | Способы лечения отторжения трансплантата с использованием доменного антитела, направленного против cd40l | |
EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
EA202190235A1 (ru) | Антитела к cd33 и способы их применения | |
EA201790520A1 (ru) | Способы лечения аутоиммунного заболевания с применением доменного антитела, специфического к cd40l | |
MX2018014560A (es) | Metodos para el tratamiento de la miastenia gravis generalizada refractaria. | |
MX2019001958A (es) | Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d. | |
EA202191666A1 (ru) | Антитела к il-27 и их применение | |
EA201790437A1 (ru) | Антигенсвязывающие белки, связывающиеся с cxcr3 | |
BR112017027736A2 (pt) | anticorpo anti-cd20 tipo ii para uso no transplante de órgãos |